Clinical trial · Interventional
The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
Prospective Clinical Study of the Effect of Thalidomide Combined With Megestrol Acetate on Lymphocyte, Inflammatory Factor Regulation and Nutritional Status in Patients With Advanced Malignant Tumors
NCT03777930CI-TRIAL-00036182unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To observe the effect of thalidomide combined with megestrol acetate on lymphocyte, inflammatory factor regulation and nutritional status in patients with advanced malignant tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Therapy-Related | Therapy-Related Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy drugs | Drug | — | UNRESOLVED |
| optimal support treatment | Other | — | UNRESOLVED |
| thalidomide and megestrol acetate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- chemotherapy group
- description
- the patients were recepted chemotherapy alone
- interventionNames
- Drug: Chemotherapy drugs
- type
- EXPERIMENTAL
- label
- chemotherapy combined with TH and MG group
- description
- the patients were recepted chemotherapy combined with thalidomide and megestrol
- interventionNames
- Drug: thalidomide and megestrol acetate
- type
- EXPERIMENTAL
- label
- the best supportive treatment group
- description
- the patients were recepted the best supportive without chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced malignant tumor confirmed by histopathology or cytology (hepatocarcinoma can be clinical diagnosis) * Must be able to swallow pills * The age of the tester ≥ 18 years old * Gender is not limited * Kamofsky score \> 20 points * Estimated survival period ≥ 2 months * Childbearing age Women need negative pregnancy test * Patients voluntarily sign informed consent and receive follow-up * The tester can cooperate to observe adverse events and efficacy * All of the above conditions can be included Exclusion Criteria: * Active upper digestive tract ulcers, obvious vomiting, chronic diarrhea, intestinal obstruction, malabsorption, etc; other patients have been known to affect drug absorption, distribution, metabolism or clearance * 2 or more important organ dysfunction * Thrombosis Embolism history, except for thrombosis caused by PICC * Patients suspected of having a history of allergy to thalidomide tablets * Any significant clinical and laboratory abnormalities that researchers believe affect safety evaluators, such as: uncontrollable activity Microbial infection, grade II or above peripheral neuropathy (NCI CTC AE v4.0), congestive heart failure, myocardial infarction within 6 months, chronic kidney disease, thyroid dysfunction etc, and acceptance may bring significant metabolic or weight changes Patients with clinical disposition * Patients with mental disorders, affecting the efficacy of the assessor * During the trial period and within 3 months after the end of the trial, the subject and his partner are not willing to contraception * Any of the above can not be enrolled.
References
Publications (0)
Data not yet available
No reference posted for this study.